Malignant hypertension: effect of therapy on renin and aldosterone.
D000236:Adenoma / Q000503:physiopathology; D000310:Adrenal Gland Neoplasms / Q000503:physiopathology; D000311:Adrenal Glands / Q000473:pathology; D000328:Adult; D000450:Aldosterone / Q000097:blood* / Q000378:metabolism; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D003900:Desoxycorticosterone / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006145:Guanethidine / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006974:Hypertension, Malignant / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood* / Q000378:metabolism; D012636:Secretory Rate; D012964:Sodium / Q000097:blood / Q000378:metabolism
D000959:Antihypertensive Agents; D006146:Guanidines; D006830:Hydralazine; D003900:Desoxycorticosterone; D000450:Aldosterone; D008750:Methyldopa; D003907:Dexamethasone; D012964:Sodium; D012083:Renin; D011188:Potassium; D006145:Guanethidine